• Policy
• Pfizer tops global mkt…Samsung Biologics tops Korean mkt
• by Lee, Hye-Kyung Mar 26, 2024 06:30am

• Policy
• Sotyktu, Livtencity to be reimb from April
• by Lee, Jeong-Hwan Mar 25, 2024 05:59am

• Policy
• Expanded ‘pre-notification for change approval’
• by Lee, Hye-Kyung Mar 25, 2024 05:59am

• Policy
• Samsung Bioepis’s Soliris biosimilar is introduced
• by Lee, Tak-Sun Mar 25, 2024 05:59am

• Policy
• Economic benefits paid to doctors to be publicly disclosed
• by Lee, Jeong-Hwan Mar 22, 2024 06:08am

• Policy
• Enhertu’s price falls to KRW 70 mil range with reimb
• by Lee, Tak-Sun Mar 22, 2024 06:06am

• Policy
• National Essential Medicines to be categorized into 4 groups
• by Lee, Hye-Kyung Mar 21, 2024 05:53am

• Policy
• Gov’t raises price of Harmonilan due to unstable supply
• by Lee, Tak-Sun Mar 21, 2024 05:52am

• Policy
• MSD withdraws SGLT2 inhibitors in a row
• by Lee, Hye-Kyung Mar 20, 2024 05:44am

• Policy
• President Yoon stands on expanding quota to 2,000
• by Lee, Jeong-Hwan Mar 20, 2024 05:44am